Advanced Search

 

Study ID Status Title Patient Level Data
FFA10026 Completed A randomised, double-blind, placebo-controlled, six-way cross design study to investigate the effect of single inhaled doses of NCE and fluticasone propionate on airway responsiveness to adenosine 5’-monophosphate challenge in mild asthmatic patients. Study Listed on ClinicalStudyDataRequest.com
FFA10027 Completed A randomised, double-blind, placebo-controlled, 6-way cross-over design study to investigate the effect of 250 µg single inhaled doses of GW685698X and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) challenge in mild asthmatic patients Study Listed on ClinicalStudyDataRequest.com
FFA10028 Completed A randomised, double-blind, placebo-controlled, balanced incomplete block, multiple dose crossover study to investigate the effect of 3 Days repeat dosing of GW685698X and fluticasone propionate (1000 µg) on exhaled nitric oxide in mild to moderate asthmatic patients. Study Listed on ClinicalStudyDataRequest.com
FFA106783 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200 mcg Twice Daily, GW685698X 200 mcg and 400 mcg Once Daily in the Morning, and GW685698X 200 mcg and 400 mcg Once Daily in the Evening Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (12 years of age and older) with Persistent Asthma Study Listed on ClinicalStudyDataRequest.com
FFA109684 Completed A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent an Study Listed on ClinicalStudyDataRequest.com
FFA109685 Completed A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 250mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Low-Dose ICS Therapy Study Listed on ClinicalStudyDataRequest.com
FFA109687 Completed A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Administered Once Daily and Fluticasone Propionate Inhalation Powder 100mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy Study Listed on ClinicalStudyDataRequest.com
FFA20001 Completed A randomised, double-blind, double dummy, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GW685698X 100mcg administered once daily either in the morning or the evening and GW685698X 250mcg administered once daily in the evening all administered by inhalation via DISKHALER for 28 days in subjects with persistent bronchial asthma. Study Listed on ClinicalStudyDataRequest.com
FFR100010 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 Weeks in Pediatric Subjects Ages 2 to <12 Years with Seasonal Allergic Rhinitis (SAR) Study Listed on ClinicalStudyDataRequest.com
FFR100012 Completed A randomized, double-blind, parallel group, placebo controlled, 6-week study of the effect of GW685698X aqueous nasal spray 100mcg QD on the hypothalamic pituitary adrenocortical (HPA) axis in children 2 to 11 years of age with perennial allergic rhinitis (PAR). Study Listed on ClinicalStudyDataRequest.com
FFR10005 Completed A double blind, randomised, placebo-controlled, single and multiple intranasal dose study to investigate the safety, tolerability and pharmacokinetics of GW685698 in Japanese healthy male subject.
FFR10006 Completed A two cohort, randomised, single-blind, two-way crossover design study to assess the effects of single doses of nasally administered fluticasone propionate (400 mcg) and a new chemical entity (NCE) on nuclear translocation of the glucocorticoid receptor, using biopsy, in male healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
FFR10008 Completed A non-randomized, open label, two period cross-over study to determine the excretion balance and pharmacokinetics of [14C]-GW685698, administered as single doses of an oral solution and an intravenous infusion to healthy adult male subjects Study Listed on ClinicalStudyDataRequest.com
FFR10010 Completed A randomised, open label, 2-way cross-over study to assess the absolute bioavailability of GW685698X administered intranasally in healthy male and female subjects Study Listed on ClinicalStudyDataRequest.com
FFR100652 Completed Clinical Evaluation of GW685698 for Seasonal Allergic Rhinitis -A Placebo-controlled Study to Determine the Non-inferiority of GW685698 over Fluticasone Propionate Using a Double-blind Manner-
FFR100688 Completed Study of Perennial Allergic Rhinitis -Long term treatment study-
FFR101747 Completed A Randomised, Double-Blind, Placebo-Controlled, Two-Week Crossover, Knemometric Assessment of the Effect of Fluticasone Furoate Nasal Spray 100mcg Once Daily on Short-Term Growth in Children Aged 6 to 11 Years with Seasonal and/or Perennial Allergic Rhinitis Study Listed on ClinicalStudyDataRequest.com
FFR101782 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis Study Listed on ClinicalStudyDataRequest.com
FFR101816 Completed A Randomized, Double Blind, Placebo-Controlled, Single-Dose, Parallel-Group Study to Evaluate the Onset of Action of a Single Dose of Intranasal GW685698X Aqueous Nasal Spray 100mcg in Adolescent and Adult Subjects (12 years of age and older) with Seasonal Allergic Rhinitis Exposed to Ragweed Pollen in an Allergen Challenge Chamber Study Listed on ClinicalStudyDataRequest.com
FFR103184 Completed A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Two Week Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis in Europe Study Listed on ClinicalStudyDataRequest.com
FFR104503 Completed A Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Center, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg QD via Nasal Biopsy in Subjects 18 Years of Age with Perennial Allergic Rhinitis (PAR) Study Listed on ClinicalStudyDataRequest.com
FFR104861 Completed See Detailed Description Study Listed on ClinicalStudyDataRequest.com
FFR105693 Completed A Randomized, Single-Blind, Cross-Over, Multicenter Study to Validate the Preference Module of the Experience with Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) Administered to Adult Subjects with Seasonal Allergic Rhinitis during a Three-week Cross-over Study Study Listed on ClinicalStudyDataRequest.com
FFR106080 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 6 Weeks in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR) Study Listed on ClinicalStudyDataRequest.com
FFR110537 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older with Perennial Allergic Rhinitis Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.